ReleaseWire Connect

DelveInsights, Adenomas-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Adenomas.

DelveInsights, Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Adenocarcinoma Of The Gastroesophageal Junction.

DelveInsights, Acute Spinal Cord Injury-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Spinal Cord Injury.

DelveInsights, Acute Sensorineural Hearing Loss-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Sensorineural Hearing Loss.

DelveInsights, Acute Respiratory Distress Syndrome-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Respiratory Distress Syndrome.

DelveInsights, Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Renal Failure (ARF) (Acute Kidney Injury).

DelveInsights, Acute Promyelocytic Leukemia-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Promyelocytic Leukemia.

DelveInsights,T Cell Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under T Cell Inhibitors. This report provides information on the therapeutic development based on the T Cell Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Telomerase Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Telomerase Inhibitors. This report provides information on the therapeutic development based on the Telomerase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

DelveInsights,Thioredoxin Reductase Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Thioredoxin Reductase Inhibitors. This report provides information on the therapeutic development based on the Thioredoxin Reductase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.